Measurement of crosslinked fibrin derivatives by a new reagent in patients with thromboembolic diseases.

概要

論文の詳細を見る
In patients with various thromboembolic diseases and normal subjects, plasma levels of crosslinked fibrin derivatives (XDP) were measured by a latex agglutination procedure using a new monoclonal antibody. Plasma XDP was undetectable (<1μg/ml) in all normal subjects, and in all patients with chronic arterial or venous thromboembolic diseases. It was elevated in 2 of 6 patients with acute venous thromboembolism, in 3 of 13 patients with acute arterial thromboembolism, and in all 18 patients with disseminated intravascular coagulation (DIC). In patients with DIC, XDP values correlated well with currently used FDP, and changed in parallel with the clnical course of DIC. Following the fibrinolytic therapy, plasma XDP level increased in 4 of 12 patients studied. It was suggested that this new reagent for the quantitation of XDP is useful for the assessment of secondary fibrinolysis, although it is not sensitive to mild elevation of XDP.
一般社団法人日本血栓止血学会の論文